

Supplementary Table 2. Socio-demographic and clinical characteristics associated with virological failure (VF) (viral load >1,000 copies/mL) among study participants (n=209). Crude odds ratios from logistic regression analyses.

	N (%) or median (IQR)						cOR	95%CI	p-value
	Total		VL≤1000		VL>1000				
			copies/mL		copies/mL				
	(n=209) ^a		(n=171)		(n=37)				
Biological sex									
Male	34	(16.35)	28	(16.28)	6	(16.22)	Ref.		
Female	175	(83.73)	144	(83.72)	31	(83.78)	0.96	0.38-2.43	0.925
Age (years)	38	(31-44)	37	(31-44)	39	(34-46)	1.03	0.98-1.07	0.246
Employment									
Employed	43	(20.57)	38	(22.09)	5	(13.51)	Ref.		
Part-time	21	(10.10)	14	(8.14)	7	(18.92)	3.62	1.03-12.70	0.045 ^b
Not employed	145	(69.38)	120	(69.77)	25	(67.57)	1.48	0.55-3.99	0.437
Marital status									
Married ^c	58	(27.75)	51	(29.65)	7	(18.92)	Ref.		
Single	139	(66.51)	112	(65.12)	27	(72.97)	1.68	0.70-4.02	0.244
Divorced	7	(3.35)	7	(4.07)	0	(0.00)	0.46	0.02-8.86	0.605
Widowed	5	(2.39)	2	(1.16)	3	(8.11)	9.61	1.60-57.85	0.013 ^b
Educational level									
No primary school	10	(4.78)	6	(3.49)	4	(10.81)	Ref.		
Primary school	135	(64.59)	112	(65.12)	23	(62.16)	0.30	0.08-1.09	0.067 ^b
Secondary school	58	(27.75)	49	(28.49)	9	(24.32)	0.28	0.07-1.11	0.070 ^b
Post-secondary school	2	(0.96)	1	(0.58)	1	(2.70)	1.44	0.11-18.73	0.779
University	4	(1.91)	4	(2.33)	0	(0.00)	0.16	0.01-3.78	0.256
BMI ^d (n=202)									
Normal weight	58	(28.71)	46	(27.88)	12	(32.43)	Ref		
Underweight	2	(0.99)	1	(0.61)	1	(2.70)	3.72	0.35-38.92	0.273
Overweight	63	(31.19)	50	(30.30)	13	(35.14)	0.99	0.42-2.37	0.990
Obesity	79	(39.11)	68	(41.21)	11	(29.73)	0.62	0.26-1.51	0.296
Previous confirmed COVID-19 diagnosis									
	7	(3.35)	5	(2.91)	2	(5.41)	2.14	0.46-9.99	0.331

Previous COVID-19 hospitalization	1	(0.48)	1	(0.58)	0	(0.00)	1.52	0.06-38.16	0.797
Pregnancy (n=175)									
No or unknown ^e	170	(97.14)	141	(97.92)	29	(93.55)	Ref.		
Yes	5	(2.86)	3	(2.08)	2	(6.45)	3.43	0.64-18.21	0.149
Hypertension	22	(10.53)	17	(9.88)	5	(13.51)	1.50	0.54-4.21	0.438
Diabetes	3	(1.44)	2	(1.16)	1	(2.70)	2.80	0.36-21.89	0.326
Hepatitis B (n=65)	3	(4.62)	1	(2.44)	2	(8.33)	3.00	0.37-24.23	0.303
Epilepsy	3	(1.44)	2	(1.16)	1	(2.70)	2.80	0.36-21.89	0.326
Symptoms at the study visit ^f	4	(1.91)	3	(1.74)	1	(2.70)	1.99	0.28-13.93	0.488
Current TB	1	(0.48)	0	(0.00)	1	(2.70)	14.18	0.57-355.02	0.107
Previous or current TB treatment	51	(24.40)	39	(22.67)	12	(32.43)	1.66	0.77-3.56	0.195
WHO stage at ART initiation									
Stage 1 or 2	164	(78.47)	136	(79.07)	28	(75.68)	Ref.		
Stage 3 or 4	45	(21.53)	36	(20.93)	9	(24.32)	1.25	0.55-2.83	0.598
WHO stage at the study visit									
Stage 1 or 2	159	(76.08)	132	(76.74)	27	(72.97)	Ref.		
Stage 3 or 4	50	(23.92)	40	(23.26)	10	(27.03)	1.25	0.57-2.76	0.583
IP-10 LFA reading ^g (n=208)	16.2	(11.9-22.8)	14.6	(11.3-20.0)	24	(17.6-36.3)	2.38 ^h	1.66-3.40	<0.001
Days since last VL	7	(4-14)	8	(5-14)	6	(2-12)	0.97	0.93-1.02	0.233
Years since ART initiation	6.5	(4.2-9.4)	6.33	(4.2-9.0)	7.50	(4.8-11.1)	1.09	0.99-1.20	0.072
Years since HIV diagnosis	7	(4-10)	6	(4-9)	8	(5-12)	1.11	1.01-1.22	0.026
Missed ART ⁱ									
None	182	(87.08)	158	(91.86)	24	(64.86)	Ref.		
At least once dose a month	27	(12.92)	14	(8.14)	13	(35.14)	6.02	2.56-14.16	<0.001
Current ART regimen									
TDF+3TC+DTG	174	(83.25)	150	(87.21)	24	(64.86)	Ref.		
TDF+FTC+EFV	21	(10.05)	14	(8.14)	7	(18.92)	3.18	1.19-8.46	0.021
Others	14	(6.70)	8	(4.65)	6	(16.22)	4.70	1.55-14.21	0.006

Legend of table:

^a For those variables with missing values, the total number of observations included is indicated next to the name of the variable.

^b This category was not included in the multivariable analysis because of the small n and because it has not the potential to be a factor included in the ART monitoring algorithm.

^c This category includes married, civil union or legal partnership.

^d BMI ranges: normal weight: 18.5-24.9 kg/m², underweight: <18.5 kg/m², overweight: 25-29.9 kg/m²; obesity: ≥30 kg/m².

^e All of them were unknown, except one.

^f After COVID-19 screening, symptoms assessed were fever, night sweats, myalgia, fatigue, headache, diarrhoea and skin rash

^g IP-10 LFA values were log-transformed for a better adjustment of skewed data.

^h For OR calculation, IP-10 reading values were categorized by increments of 10-units. Therefore, an increase of 10 units in the IP-10 reading value corresponds to a 2.38 OR of having VF.

ⁱ Self-reported ART adherence.

Abbreviations: 3TC: Lamivudine, ART: antiretroviral therapy, BMI: body mass index, CI: confidence interval, cOR: crude odds ratio, DTG: dolutegravir, FTC: emtricitabine, EFV: efavirenz, IQR: interquartile range, LFA: lateral flow assay, Ref: reference category, TB: tuberculosis, TDF: tenofovir, VL: viral load.